Department of Public Health and Infectious Diseases, University of Rome "Sapienza", 00185 Rome, Italy.
Department of Maternal and Child Health and Urology, University of Rome "Sapienza", 00161 Rome, Italy.
Nutrients. 2024 Oct 14;16(20):3469. doi: 10.3390/nu16203469.
BACKGROUND/OBJECTIVES: the vaginal microbiota is known to confer protection in the genital ecosystem, due to the predominance of different species, playing a crucial role in women's health; alterations in the composition of the microbial communities in the vagina can be associated with the development of bacterial vaginosis (BV). Current therapy for BV involves oral or intravaginal administration of metronidazole or clindamycin, albeit the high recurrence rates suggest a need for alternative therapeutic tools, such as probiotics. Herein, the diversity and composition of vaginal microbiota in women with asymptomatic BV was investigated before and after the oral administration of a multi-strain probiotic formulation.
a prospective observational pilot study with pre-post design was carried out from 1 June 2022, to 31 December 2022, on reproductive-age women with asymptomatic BV, as diagnosed via Nugent score, and matched healthy controls. The probiotic was administered to all study participants as acid-resistant oral capsules (twice daily), and a vaginal swab was collected at baseline and after 2 months of treatment, for the metagenomic analysis of 16s rDNA.
the diversity and richness of the vaginal microbiota in women with BV were significantly reduced after 2 months of supplementation with the oral probiotic, as evidenced by measures of α-diversity. Interestingly, some bacterial genera typically associated with dysbiosis, such as spp., were significantly decreased; whereas, at the same time, spp. Doubled.
our preliminary results suggest that the multi-strain oral probiotic is a beneficial treatment specifically targeting the dysbiotic vaginal microenvironment.
背景/目的：阴道微生物群由于不同物种的优势，在生殖生态系统中提供保护，在女性健康中起着至关重要的作用；阴道微生物群落组成的改变可能与细菌性阴道病（BV）的发展有关。目前，BV 的治疗方法包括口服或阴道内给予甲硝唑或克林霉素，但高复发率表明需要替代治疗工具，如益生菌。在此，我们研究了无症状 BV 女性在口服多菌株益生菌制剂前后阴道微生物群的多样性和组成。
一项前瞻性观察性试点研究，采用前后设计，于 2022 年 6 月 1 日至 2022 年 12 月 31 日对诊断为 Nugent 评分的无症状 BV 和匹配的健康对照的育龄妇女进行。所有研究参与者均给予耐酸口服胶囊（每日两次）作为益生菌，在基线和治疗 2 个月后采集阴道拭子，用于 16s rDNA 的宏基因组分析。
BV 女性阴道微生物群的多样性和丰富度在口服益生菌补充 2 个月后显著降低，α多样性的测量结果证实了这一点。有趣的是，一些与失调相关的细菌属，如 spp.，显著减少；与此同时， spp. 增加了一倍。
我们的初步结果表明，多菌株口服益生菌是一种针对失调阴道微环境的有益治疗方法。
